The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Diabetes

• Publication date

  2001-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2337/DIABETES.50.9.1959PMID 11522660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia.

  2001cited by this paper
• A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11.

  2001cited by this paper
• The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily.

  2000cited by this paper
• PACAP Activates Pancreatic α‐Cells in a Glucose Independent Manner

  2000cited by this paper
• THE ORIGIN AND FUNCTION OF THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/GLUCAGON SUPERFAMILY

  2000cited by this paper
• PACAP activates pancreatic alpha-cells in a glucose independent manner.

  2000cited by this paper
• PACAP contributes to insulin secretion after gastric glucose gavage in mice.

  2000cited by this paper
• Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

  2000cited by this paper
• PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

  2000cited by this paper
• The Effects of PACAP on Insulin Secretion and Glucose Disposal Are Altered by Adrenalectomy in Mice

  2000cited by this paper
• Intraperitoneal PACAP Administration Decreases Blood Glucose in GK Rats, and in Normal and High Fat Diet Mice

  2000cited by this paper
• PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion.

  1999cited by this paper
• Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin.

  1999cited by this paper
• Pituitary adenylate cyclase-activating polypeptide in intrinsic and extrinsic nerves of the rat pancreas

  1999cited by this paper
• Functional Characterization of Structural Alterations in the Sequence of the Vasodilatory Peptide Maxadilan Yields a Pituitary Adenylate Cyclase-activating Peptide Type 1 Receptor-specific Antagonist*

  1999cited by this paper
• Molecular and Functional Characterization of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38)/Vasoactive Intestinal Polypeptide Receptors in Pancreatic β-Cells and Effects of PACAP-38 on Components of the Insulin Secretory System1.

  1999cited by this paper
• Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cells.

  1999cited by this paper
• Potentiators and Inhibitors of Insulin Secretion

  1999cited by this paper
• PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice.

  1998cited by this paper
• The augmentation of pituitary adenylate cyclase-activating polypeptide (PACAP) in streptozotocin-induced diabetic rats.

  1998cited by this paper
• Protein Kinase A Inhibition and PACAP‐Induced Insulin Secretion in HIT‐T15 Cells a

  1998cited by this paper
• Evidence for Contribution by Increased Cytoplasmic Na+ to the Insulinotropic Action of PACAP38 in HIT-T15 Cells*

  1998cited by this paper
• Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes.

  1998cited by this paper
• Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.

  1998cited by this paper
• PACAP in Visceral Afferent Nerves Supplying the Rat Digestive and Urinary Tracts a

  1998cited by this paper
• PACAP and PACAP receptors in insulin producing tissues: localization and effects.

  1998cited by this paper
• International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

  1998cited by this paper
• Maxadilan, the Vasodilator from Sand Flies, Is a Specific Pituitary Adenylate Cyclase Activating Peptide Type I Receptor Agonist*

  1997cited by this paper
• Pituitary adenylate cyclase‐activating polypeptide (PACAP) is an islet substance serving as an intra‐islet amplifier Of glucose‐induced insulin secretion in rats

  1997cited by this paper
• Development of high affinity selective VIP1 receptor agonists.

  1997cited by this paper
• Pancreatic endocrine responses to the peptides VIP and PACAP in the conscious calf

  1997cited by this paper
• Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans.

  1997cited by this paper
• PACAP-(1-38) as neurotransmitter in pig pancreas: receptor activation revealed by the antagonist PACAP-(6-38).

  1997cited by this paper
• Presynaptic sympathetic mechanism in the insulinostatic effect of epinephrine in mouse pancreatic islets.

  1997cited by this paper
• The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.

  1997cited by this paper
• Pituitary adenylate cyclase activating peptide (PACAP) in salivary glands of the rat: origin, and secretory and vascular effects.

  1997cited by this paper
• Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.

  1997cited by this paper
• Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogs.

  1997cited by this paper
• Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells.

  1996cited by this paper
• Distribution of two VIP-related peptides, helospectin and pituitary adenylate cyclase activating peptide (PACAP), in the human upper respiratory system.

  1996cited by this paper
• A Wortmannin-sensitive Signal Transduction Pathway Is Involved in the Stimulation of Insulin Release by Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase-activating Polypeptide (*)

  1996cited by this paper
• Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat

  1996cited by this paper
• Alternative Splicing in the N-terminal Extracellular Domain of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Receptor Modulates Receptor Selectivity and Relative Potencies of PACAP-27 and PACAP-38 in Phospholipase C Activation*

  1996cited by this paper
• Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats

  1996cited by this paper
• Tissue Specific Expression of Different Human ReceptorTypes for Pituitary Adenylate Cyclase Activating Polypeptideand Vasoactive Intestinal Polypeptide: Implications fortheir Role in Human Physiology

  1996cited by this paper
• Molecular Cloning of a Novel Variant of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Receptor That Stimulates Calcium Influx by Activation of L-type Calcium Channels*

  1996cited by this paper
• VIP‐ and PACAP‐mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin‐ and apamin‐sensitive K+ channels

  1996cited by this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland.

  1996cited by this paper
• Cloning and Characterization of the Signal Transduction of Four Splice Variants of the Human Pituitary Adenylate Cyclase Activating Polypeptide Receptor

  1996cited by this paper
• Role of PACAP in the Regulation of Gastrointestinal Motility

  1996cited by this paper
• A 67 kDa protein mediates pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide-stimulated insulin secretion in a hamster clonal beta-cell line.

  1995cited by this paper
• Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei.

  1995cited by this paper
• Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor.

  1995cited by this paper
• PACAP stimulates glucose output from the perfused rat liver.

  1995cited by this paper
• Pituitary adenylate cyclase-activating polypeptide induces the voltage-independent activation of inward membrane currents and elevation of intracellular calcium in HIT-T15 insulinoma cells.

  1995cited by this paper
• Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Its Receptors: Neuroendocrine and Endocrine Interaction

  1995cited by this paper
• Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro.

  1994cited by this paper
• Pituitary adenylate cyclase-activating polypeptide: effects on pancreatic-adrenal hormone secretion and glucose-lipid metabolism in normal conscious dogs.

  1994cited by this paper
• Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells.

  1994cited by this paper
• Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP).

  1993cited by this paper
• Cloning of a splice variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) type I receptor.

  1993cited by this paper
• Differential signal transduction by five splice variants of the PACAP receptor

  1993cited by this paper
• Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: Immunocytochemical and immunochemical evidence

  1993cited by this paper
• Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues.

  1993cited by this paper
• Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide.

  1993cited by this paper
• Glucose counterregulation: prevention and correction of hypoglycemia in humans.

  1993cited by this paper
• Vasoactive intestinal peptide, but not pituitary adenylate cyclase-activating peptide, modulates the responsiveness of the gonadotroph to LHRH in man.

  1993cited by this paper
• Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

  1993cited by this paper
• Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP)

  1993cited by this paper
• Stimulatory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on insulin and glucagon release from the isolated perfused rat pancreas.

  1993cited by this paper
• Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

  1993cited by this paper
• Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells

  1993cited by this paper
• Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

  1993cited by this paper
• Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor.

  1993cited by this paper
• Pituitary adenylate cyclase activating polypeptide-27 (PACAP-27) inhibits pentagastrin-stimulated gastric acid secretion in conscious rats

  1992cited by this paper
• Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.

  1992cited by this paper
• Primary Structure and Characterization of the Precursor to Human Pituitary Adenylate Cyclase Activating Polypeptide

  1992cited by this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse

  1992cited by this paper
• Pituitary adenylate cyclase-activating polypeptide stimulates secretion in T84 cells.

  1992cited by this paper
• Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research

  1992cited by this paper
• Pituitary Adenylate Cyclase Activating Polypeptide is a Potent Vasodilator in Humans

  1992cited by this paper
• Pituitary adenylate cyclase activating polypeptide stimulates insulin release from the isolated perfused rat pancreas.

  1992cited by this paper
• Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene.

  1992cited by this paper
• Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes.

  1991cited by this paper
• The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1–27) and PACAP (1–38)) interact with distinct receptors on rat pancreatic AR 4‐2J cell membranes

  1991cited by this paper
• Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract

  1991cited by this paper
• Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding.

  1991cited by this paper
• Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38).

  1990cited by this paper
• Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells.

  1989cited by this paper
• The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic-AMP-dependent and -independent mechanisms.

  1987cited by this paper
• New developments in the incretin concept

  1985cited by this paper
• Sham feeding-induced cephalic phase insulin release in the rat.

  1982cited by this paper
• NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.

  1964cited by this paper
• PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.

  1964cited by this paper
• DEFECT OF ORGANIZATION IN THE EXTERNAL EAR.

  1824cited by this paper

• Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy

  2025cites this paper
• The hypoglycemic potential of phenolics from functional foods and their mechanisms

  2023cites this paper
• Control of myeloid cell functions by nociceptors

  2023cites this paper
• Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes

  2022cites this paper
• Analysis of Half a Billion Datapoints Across Ten Machine-Learning Algorithms Identifies Key Elements Associated With Insulin Transcription in Human Pancreatic Islet Cells

  2022cites this paper
• The PACAP Paradox: Dynamic and Surprisingly Pleiotropic Actions in the Central Regulation of Energy Homeostasis

  2022cites this paper
• Analysis of half a billion datapoints across ten machine-learning algorithms identify key determinants of insulin gene transcription

  2021cites this paper
• Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review

  2021cites this paper
• Pancreas-Brain Crosstalk

  2021cites this paper
• PACAP stimulates insulin secretion by PAC1 receptor and ion channels in β-cells.

  2019cites this paper
• Studies of cAMP and Ca2+ signaling in pancreatic islet cells

  2018cites this paper
• Author Correction: Beta cell connectivity in pancreatic islets: a type 2 diabetes target?

  2018cites this paper
• HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes

  2018cites this paper
• Immunochemical Identification of Immunoreactive Ghrelin in Tea Plant, Camellia sinensis (L) O. Kuntze

  2018cites this paper
• ADCYAP1 (adenylate cyclase activating polypeptide 1 (pituitary))

  2017cites this paper
• Treatment Strategies for Type 2 Diabetes Based on Incretin Action

  2016cites this paper
• Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function

  2016cites this paper
• Presence and Role of PACAP in Endocrine Glands of Mammals

  2016cites this paper
• Recent Advancement in Treatment of Type-II Diabetes Mellitus : A Review

  2015cites this paper
• p13 overexpression in pancreatic β-cells ameliorates type 2 diabetes in high-fat-fed mice.

  2015cites this paper
• Neuropeptides and islet hormone secretion

  2015cites this paper
• Beta cell connectivity in pancreatic islets: a type 2 diabetes target?

  2015cites this paper
• Role of ZAC1 in transient neonatal diabetes mellitus and glucose metabolism.

  2015cites this paper
• Beta cell connectivity in pancreatic islets: a type 2 diabetes target?

  2014cites this paper
• Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

  2014cites this paper
• The Effect of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Islet Transplantation

  2013cites this paper
• Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice.

  2013cites this paper
• Cyclic AMP dynamics in the pancreatic β-cell

  2012cites this paper
• A Pattern Search Method for Discovering Conserved Motifs in Bioactive Peptide Families

  2011cites this paper
• A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes.

  2010cites this paper
• Trophic Effects of PACAP on Pancreatic Islets: A Mini-Review

  2010cites this paper
• The role of DcR3 in systemic lupus erythematosus and islet β-Cell viability and function

  2009cites this paper
• Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

  2009cites this paper
• Effect of pituitary adenylate cyclase-activating polypeptide in islet transplantation.

  2009cites this paper
• Pancreas: Embryology, Anatomy, and Physiology

  2009cites this paper
• Markedly reduced white adipose tissue and increased insulin sensitivity in adcyap1-deficient mice.

  2008cites this paper
• Feeding and metabolism in mice lacking pituitary adenylate cyclase-activating polypeptide.

  2008cites this paper
• Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications

  2008cites this paper
• Role of Pituitary Adenylate Cyclase‐Activating Polypeptide in the Pancreatic Endocrine System

  2008cites this paper
• Incretins and Regulation of Insulin Secretion

  2008cites this paper
• Neurotrophic Actions of PACAP-38 and LIF on Human Neuroblastoma SH-SY5Y Cells

  2008cites this paper
• Embryonic stem cell therapy for diabetes mellitus.

  2007cites this paper
• Knocked down and out: PACAP in development, reproduction and feeding.

  2007cites this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cites this paper
• Expression of islet inducible nitric oxide synthase and inhibition of glucose-stimulated insulin release after long-term lipid infusion in the rat is counteracted by PACAP27.

  2007cites this paper
• Role of VIP and PACAP in islet function.

  2007cites this paper
• Genome-wide search for susceptibility genes to type 2 diabetes in West Africans: potential role of C-peptide.

  2007cites this paper
• G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.

  2007cites this paper
• PACAP in the glucose and energy homeostasis: physiological role and therapeutic potential.

  2007cites this paper
• Neuropeptide signaling and hydrocephalus: SCO with the flow.

  2006cites this paper
• Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

  2006cites this paper
• Uncovering conserved patterns in bioactive peptides in Metazoa.

  2006cites this paper
• The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice.

  2006cites this paper
• New Insights into the Central PACAPergic System from the Phenotypes in PACAP‐ and PACAP Receptor‐Knockout Mice

  2006cites this paper
• Systemic administration of pituitary adenylate cyclase-activating polypeptide maintains beta-cell mass and retards onset of hyperglycaemia in beta-cell-specific calmodulin-overexpressing transgenic mice.

  2005cites this paper
• What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

  2005cites this paper
• Diabetes mellitus and its treatment

  2005cites this paper
• Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs

  2005cites this paper
• Glucagon- Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

  2005cites this paper
• New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

  2005cites this paper
• PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis.

  2005cites this paper
• Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines

  2005cites this paper
• New drugs for the treatment of diabetes mellitus

  2004cites this paper
• Structural and functional evolution of gonadotropin-releasing hormone (GnRH) and pituitary adenylate cyclase-activating polypeptide (PACAP) in chordates

  2004cites this paper
• Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.

  2004cites this paper
• Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM.

  2004cites this paper
• Vertebrate development and physiology in response to augmented pituitary adenylate cyclase-activating polypeptide (PACAP)

  2004cites this paper
• Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

  2004cites this paper
• Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues.

  2004cites this paper
• Targeting β‐cell cyclic 3′5′adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review

  2004cites this paper
• Overexpression of Pituitary Adenylate Cyclase-Activating Polypeptide in Islets Inhibits Hyperinsulinemia and Islet Hyperplasia in Agouti Yellow Mice

  2004cites this paper
• Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice.

  2004cites this paper
• β-Cell-targeted Overexpression of Phosphodiesterase 3B in Mice Causes Impaired Insulin Secretion, Glucose Intolerance, and Deranged Islet Morphology*

  2004cites this paper
• Defective insulin secretion during total parenteral nutrition in rat and its normalization by pituitary adenylate cyclase-activating polypeptide 27.

  2004influential citation
• PACAPAND THE ENDOCRINE PANCREAS

  2003cites this paper
• Consequences of PACAP Gene Knockout

  2003cites this paper
• Gut peptides and type 2 diabetes mellitus treatment

  2003cites this paper
• PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets.

  2003cites this paper
• The Role of Phosphodiesterase 3B in the Regulation of Insulin Secretion

  2003cites this paper
• Neuropeptides and Insulin Secretion

  2003cites this paper
• PACAP and the Endocrine Pancreas

  2003cites this paper
• Role for VPAC2 receptor-mediated signals in pancreas development.

  2003cites this paper
• Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes.

  2003cites this paper
• Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes.

  2003influential citation
• [Physiology of the neuropeptides].

  2002cites this paper
• The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice.

  2002cites this paper
• Mouse pituitary adenylate cyclase-activating polypeptide (PACAP): gene, expression and novel splicing.

  2002cites this paper
• Neuropeptides and Islet Function

  2002cites this paper
• PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways.

  2002cites this paper
• Targeted disruption of the gene for pituitary adenylate cyclase-activating polypeptide (PACAP) in mouse results in metabolic dysfunction.

  2002cites this paper